Any adverse events · people with cancer who have febrile neutropenia
It is very uncertain whether adverse events with anti‐gram‐positive antibiotics changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of % predicted FVC · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline (per month) of functional rating scale (over a period of 9 months) Measured by ALSFRS‐R · people with ALS/MND
1 finding from 1 review
Intervention not reported
Health‐related quality of life Short Form 12 Health Survey (SF‐12) · people with ALS/MND
1 finding from 1 review
Intervention not reported
Adverse events · people with ALS/MND
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES showed no clear difference in total DVT compared with alternative prophylaxis (low certainty).
1 finding from 1 review
PE · participants at risk of venous thromboembolism
NMES showed no clear difference in PE compared with no prophylaxis (low certainty).
1 finding from 1 review
Total VTE · participants at risk of venous thromboembolism
NMES may leads to lower total VTE compared with no prophylaxis (low certainty).
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES may leads to higher total DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
NMES showed no clear difference in asymptomatic DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Symptomatic DVT · participants at risk of venous thromboembolism
NMES showed no clear difference in symptomatic DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
PE · participants at risk of venous thromboembolism
1 finding from 1 review
Total VTE · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES showed no clear difference in total DVT compared with dextran 40 (low certainty).
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
NMES showed no clear difference in asymptomatic DVT compared with alternative prophylaxis (low certainty).
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review